Fig. 1: Study design.
From: Targeting neddylation and sumoylation in chemoresistant triple negative breast cancer
Schematic representation of the ARTEMIS clinical trial showing PDX models established at clinical presentation (Pre), after four cycles of Adriamycin and cyclophosphamide (AC, Mid), and after completion of NACT (Post). Patient IDs (PiD) and Patient in Mouse (PIM) IDs that were established at each time point are shown below. Color code denotes matched patient/PDX serial models.
